Results from Phase 2 RAINFOLTM-01 trial (B1 cohort) showed that with a median on-study follow-up of 48 weeks, Rina-S 120 mg/m2 led to a confirmed objective response rate (ORR) of 55.6% and median ...

Elizabeth K. Lee, MD, a medical oncologist in the gynecologic oncology program at Dana-Farber, presented results from a phase ...

We’re using evolution to attack tumors,” said study senior author, Ashish H. Shah, M.D. Viral mimicry was first successfully used to make ovarian cancer more susceptible to ICI in 2015. It has since ...